Paramount Licensing pays homage to ‘Tommy Boy’
LOS ANGELES A new t-shirt on the market pays tribute to the hit comedy film “Tommy Boy.”
The t-shirt features a retro white “Callahan Auto Parts” logo, referencing the auto parts factory in the town of Sandusky, Ohio, which factory heir Tommy (played by the late Chris Farley) must save from going out of business.
The shirt, developed by Paramount Licensing and Now And Zen Productions can be found in Target’s pop culture display, retailing at $7.99.
Season 13 of ‘The Simpsons’ arrives on Blu-ray, DVD this summer
LOS ANGELES Twentieth Century Fox Home Entertainment is bringing the residents of Springfield to Blu-ray and DVD this August.
The complete 13th season of television’s longest running comedy — “The Simpsons” — will arrive Aug. 24. The season features 22 episodes including two noteworthy standouts: the Simpsons’ trip to Brazil in “Blame It On Lisa” and Homer’s foray into medicinal marijuana in “Weekend at Burnsie’s.” Once again, a talented line-up of guest stars lend their voices including Ben Stiller, Reese Witherspoon, Richard Gere, Pierce Brosnan, Matthew Perry, R.E.M. and Paul Newman.
“The Simpsons” the complete 13th season is packed with special features including deleted scenes, audio commentaries on every episode, featurettes, storyboards, animatics, easter eggs and much more. The Blu-ray release also includes specially created menus with additional animation that does not appear on the DVD. The set comes in collectible packaging modeled after Springfield’s “special” child, Ralph Wiggum. The Blu-ray and DVD will be available for the suggested retail price of $59.99 and $49.98, respectively.
Decision Resources: Atrial fibrillation treatments will expand market size to $7 billion
WALTHAM, Mass. Launch and use of new heart drugs will drive the market for drugs to treat atrial fibrillation and increase its size to nearly $7 billion in less than a decade, according to a new report from market analysis firm Decision Resources.
The report found that new drugs from Boehringer Ingelheim, Sanofi-Aventis and partnerships between Bayer and Johnson & Johnson and Pfizer and Bristol-Myers Squibb –– specifically anticoagulant and antiarrhythmic drugs –– will drive most of the atrial fibrillation drug market in developed countries and increase it more than eight-fold, from $843 million in 2009 to $6.8 billion in 2019.
The drugs cited include Boehringer Ingelheim’s Pradaxa (dabigatran etexilate), Sanofi-Aventis’ Multaq (dronedarone), apixan, by Bristol and Pfizer, and Xarelto (rivaroxaban), by Bayer and J&J. These drugs are expected to drive three-quarters of the market in the United States, United Kingdom, France, Italy, Spain, Germany and Japan.
The report found that while Multaq would face challenges due to competition from another Sanofi drug, Cordarone (amiodarone), which also is available as a generic, it would likely have sales of more than $650 million in 2019.